Maximum Dose of Bystolic (Nebivolol)
The maximum recommended dose of Bystolic (nebivolol) is 40 mg once daily for hypertension. 1
FDA-Approved Dosing Guidelines
Starting dose: For most patients with hypertension, the recommended starting dose is 5 mg once daily, with or without food, as monotherapy or in combination with other agents. 1
Titration schedule: For patients requiring further blood pressure reduction, the dose can be increased at 2-week intervals up to the maximum of 40 mg once daily. 1
Dosing frequency: A more frequent dosing regimen than once daily is unlikely to provide additional benefit. 1
Special Population Adjustments
Severe Renal Impairment
In patients with severe renal impairment (creatinine clearance <30 mL/min), the recommended initial dose is 2.5 mg once daily, with slow upward titration as needed. 1
Bystolic has not been studied in patients receiving dialysis. 1
Moderate Hepatic Impairment
In patients with moderate hepatic impairment, the recommended initial dose is 2.5 mg once daily, with slow upward titration as needed. 1
Bystolic has not been studied in patients with severe hepatic impairment and is therefore not recommended in that population. 1
Elderly Patients
- No dose adjustment is necessary for elderly patients. 1
CYP2D6 Poor Metabolizers
- No dose adjustments are necessary for patients who are CYP2D6 poor metabolizers, as the clinical effect and safety profile observed in poor metabolizers were similar to those of extensive metabolizers. 1
Clinical Evidence Supporting Dosing
In clinical trials for hypertension, nebivolol doses ranging from 1.25 to 40 mg were studied over 12 weeks, with most studies showing increasing blood pressure response to doses above 5 mg. 1
The most commonly used dose in clinical trials for hypertension was 5 mg daily, though no significant further decreases in blood pressure were shown with higher doses in some studies. 2
In the SENIORS trial for heart failure in elderly patients (≥70 years), nebivolol was titrated from 1.25 mg once daily to a target of 10 mg once daily, with a mean maintenance dose of 7.7 mg. 3
Important Clinical Considerations
Nebivolol is a highly selective β₁-adrenergic receptor blocker with vasodilatory properties mediated through nitric oxide pathways, which distinguishes it from traditional beta-blockers. 2, 4
The drug is highly lipophilic and rapidly absorbed after oral administration, with extensive hepatic metabolism through the CYP2D6 system. 2, 4
In a large real-world cohort study of 99,942 patients with hypertension, nebivolol was associated with significantly greater reductions in systolic blood pressure (-11.0 mmHg), diastolic blood pressure (-8.1 mmHg), and heart rate (-7.3 bpm) compared with carvedilol and other beta-blockers. 5
A systematic review and meta-analysis of 91 randomized controlled trials involving 7,737 participants demonstrated that nebivolol significantly reduced office systolic BP by 6.01 mmHg and diastolic BP by 5.01 mmHg compared to placebo, with the effect remaining independent of nebivolol dose, age, sex, trial duration, BMI, baseline diabetes, heart failure, and baseline blood pressure. 6